Efficacy and safety of different rivaroxaban medications in prevention and treatment of thromboembolic disease in very old patients
10.3969/j.issn.1009-0126.2018.04.008
- VernacularTitle:不同方案利伐沙班防治高龄老年血栓栓塞疾病的有效性和安全性研究
- Author:
Jiefeng REN
1
;
Quanjin SI
Author Information
1. 解放军总医院南楼心内科
- Keywords:
thromboembolism;
hemorrhage;
anticoagulants;
risk factors
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2018;20(4):367-370
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the efficacy and safety of different rivaroxaban medications in prevention and treatment of thromboembolic disease in very old patients.Methods One hundred and ninety-eight very old thromboembolic disease patients were divided into low dose (2.5-7.5 mg)rivaroxaban treatment group (n =35),routine dose (10-20 mg) rivaroxaban treatment group (n=138),combined (10 mg) rivaroxaban and (75 mg) clopidogrel treatment group (n=25).Their baseline data were recorded.The incidence of major adverse thromboembolic disease and bleeding events in 3 groups was compared by Kaplan-Meiers survival analysis.Results No significant difference was found in gender,risk factors for and past history of thromboembolic disease and bleeding events,laboratory testing parameters in 3 groups (P＞0.05).The age was significantly older in low dose rivaroxaban treatment group than in routine dose rivaroxaban treatment group (90.43±5.02 vs 86.80±5.52,P=0.000).Kaplan-Meiers survival analysis showed no significant difference in the incidence of thromboembolic disease and bleeding events in 3 groups (P＞0.05).Conclusion Low dose rivaroxaban is effective in prevention and treatment of thromboembolic disease while combined clopidogrel and rivaroxaban is not only effective but also safe in prevention and treatment of thromboembolic disease in very old patients.
